Epidemiology of COVID-19 infections in haematology patients and prognostic factors for outcome: A national, multicentre retrospective study

BJH - volume 13, issue 7, november 2022

T. Mercier MD, PhD, S. Fieuws PhD, K. Theunissen MD, M-C. Ngirabacu MD, PhD, N. Straetmans MD, PhD, C. Spilleboudt MD, D. Mazure MD, V. De Wilde MD, PhD, A. De Becker MD, D. Selleslag MD, D. Breems MD, PhD, D. Deeren MD, S. Servais MD, PhD, C. Jacquy MD, H. Poirel MD, PhD, D. Van Beckhoven MD, K. Blot MD, PhD, A. Janssens MD, PhD, H. Schoemans MD, PhD


In the early weeks of the ongoing COVID-19 pandemic, little was known about the risk factors of this novel disease in haematology patients. We therefore created a national, multi-center, retrospective study via a national consortium of haematology centres in Belgium to investigate the incidence and clinical characteristics of COVID-19 in haematology patients. By combining these data with data collected through the national public health institute Sciensano and the national Belgian Cancer Registry, we were able to show that haematology patients were at an increased risk of being hospitalised with COVID-19 (1 in 250 haematology patients versus 1 in 2000 in the general population). Furthermore, we found that patients with multiple myeloma and acute leukaemia were overrepresented in these hospitalisations. Mortality at 90 days was 38% during the first wave, compared to 19.3% in the general population. We therefore conclude that haematology patients with COVID-19 are at a significantly higher risk of both hospitalisation and death.

(BELG J HEMATOL 2022;13(7):269–76)

Read more


BJH - volume 9, issue Abstract Book BSTH, february 2018

E. De Maertelaere , E. Castoldi , I. Van Haute , D. Deeren MD, K. Devreese

Read more

O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

BJH - volume 8, issue Abstract Book BHS, february 2017

X. Poiré MD, PhD, C. Graux MD, PhD, A. Ory , J. Jamart , F. Frédéric , H. Schoemans MD, PhD, P. Lewalle MD, PhD, A. De Becker MD, D. Deeren MD, Z. Berneman MD, PhD, T. Kerre MD, PhD, P. Zachée MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD

Read more

P58 Extremely elevated C – reactive protein: a bad omen for haematological patients?

BJH - volume 8, issue Abstract Book BHS, february 2017

L. Tryssesoone , D. Deeren MD

Read more

P2.02 Belgian consensus on the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria

BJH - volume 7, issue Abstract Book BHS, january 2016

dr. B. Devalet , N. Boeckx MD, PhD, B. Chatelain PharmD, C. Chatelain MD, D. Deeren MD, A. Gothot MD, PhD, S. Meers MD, PhD, T. Devos MD, PhD

Read more

P3.01 Hematopoietic progenitor cell count in mobilized peripheral blood by Sysmex XE-2100: added value in clinical practice?

BJH - volume 6, issue Abstract Book BHS, january 2015

S. Desmet , T. Maenhout , E. Moreau , I. Van Haute , D. Deeren MD

Read more